Troxerutin
Troxerutin is a semisynthetic flavonoid derived from rutin (a bioflavonoid from quercetin) that exerts venotonic, anti-inflammatory, and antioxidant effects by reducing capillary permeability and fragility. It is used to treat chronic venous insufficiency, deep vein thrombosis, and related conditions such as edema and varicose veins by improving microcirculation and reducing inflammatory mediator release. Its antioxidant properties also protect against oxidative stress-mediated endothelial damage.
الوزن الجزيئي
742,7000 g/mol
LogP
-2,40
TPSA
293,00 Ų
قاعدة ليبينسكي للخمسة
راسب
المجالات العلاجية
Pharmacokinetics (PK)
Pharmacodynamics (PD)
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(OCCO)c(OCCO)c4)oc4cc(OCCO)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
InChI
InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3/t14-,21+,23-,24+,26+,27-,28+,29+,32+,33-/m0/s1
Molecular Formula
C33H42O19
HBD / HBA
10 / 19
الروابط القابلة للدوران
15
الذرات الثقيلة
52
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
Troxerutin is a semisynthetic flavonoid derived from rutin (a bioflavonoid from quercetin) that exerts venotonic, anti-inflammatory, and antioxidant effects by reducing capillary permeability and fragility. It is used to treat chronic venous insufficiency, deep vein thrombosis, and related conditions such as edema and varicose veins by improving microcirculation and reducing inflammatory mediator release. Its antioxidant properties also protect against oxidative stress-mediated endothelial damage.
Yes, Troxerutin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3182320. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5486699. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="troxerutin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/troxerutin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/troxerutin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/troxerutin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="troxerutin"></drugfyi-drug>